scholarly journals Is DNA methylation of tumour suppressor genes epigenetic?

eLife ◽  
2014 ◽  
Vol 3 ◽  
Author(s):  
Kevin Struhl

In colorectal cancer cells, a non-epigenetic transcriptional pathway that is mediated by an oncogene maintains DNA methylation of tumour suppressor genes

2014 ◽  
Vol 723 ◽  
pp. 276-287 ◽  
Author(s):  
Katarzyna Lubecka-Pietruszewska ◽  
Agnieszka Kaufman-Szymczyk ◽  
Barbara Stefanska ◽  
Barbara Cebula-Obrzut ◽  
Piotr Smolewski ◽  
...  

2015 ◽  
Vol 13 (6) ◽  
pp. 969-981 ◽  
Author(s):  
Jing Song ◽  
Zhanwen Du ◽  
Mate Ravasz ◽  
Bohan Dong ◽  
Zhenghe Wang ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. e57709 ◽  
Author(s):  
Alexander Link ◽  
Francesc Balaguer ◽  
Yan Shen ◽  
Juan Jose Lozano ◽  
Hon-Chiu E. Leung ◽  
...  

2012 ◽  
Vol 13 (7) ◽  
pp. 542-552 ◽  
Author(s):  
Yan Shen ◽  
Masanobu Takahashi ◽  
Hyang-Min Byun ◽  
Alexander Link ◽  
Nupur Sharma ◽  
...  

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Keke Shao ◽  
Weilin Pu ◽  
Jianfeng Zhang ◽  
Shicheng Guo ◽  
Fei Qian ◽  
...  

Abstract Background Aberrant DNA methylation has been firmly established as a factor contributing to the pathogenesis of colorectal cancer (CRC) via its capacity to silence tumour suppressor genes. However, the methylation status of multiple tumour suppressor genes and their roles in promoting CRC metastasis are not well characterised. Methods We explored the methylation and expression profiles of CPEB1 (the gene encoding cytoplasmic polyadenylation element-binding protein 1), a candidate CRC tumour suppressor gene, using The Cancer Genome Atlas (TCGA) database and validated these results in both CRC cell lines and cells from Han Chinese CRC patients (n = 104). The functional role of CPEB1 in CRC was examined in experiments performed in vitro and in vivo. A candidate transcription factor capable of regulating CPEB1 expression was predicted in silico and validated by luciferase reporter, DNA pull-down, and electrophoretic mobility shift assays. Results Hypermethylation and decreased expression of CPEB1 in CRC tumour tissues were revealed by TCGA database. We also identified a significant inverse correlation (Pearson’s R = − 0.43, P < 0.001) between promoter methylation and CPEB1 expression. We validated these results in CRC samples and two CRC cell lines. We also demonstrated that up-regulation of CPEB1 resulted in significantly decreased tumour growth, migration, invasion, and tumorigenicity and promoted tumour cell apoptosis both in vitro and in vivo. We identified the transcription factors CCAAT enhancer-binding protein beta (CEBPB) and transcription factor CP2 (TFCP2) as critical regulators of CPEB1 expression. Hypermethylation of the CPEB1 promoter resulted in a simultaneous increase in the capacity for TFCP2 binding and a decreased likelihood of CEBPB binding, both of which led to diminished expression of CPEB1. Conclusions Our results identified a novel tumour-suppressive role of CPEB1 in CRC and found that hypermethylation of the CPEB1 promoter may lead to diminished expression due to decreased chromatin accessibility and transcription factor binding. Collectively, these results suggest a potential role for CPEB1 in the diagnosis and treatment of CRC.


Sign in / Sign up

Export Citation Format

Share Document